For research use only. Not for therapeutic Use.
T0070907(CAT: I003111) represents a significant breakthrough in the realm of pharmaceutical and metabolic research. As a potent and selective antagonist of the peroxisome proliferator-activated receptor gamma (PPARγ), T0070907 holds promise in modulating metabolic pathways and cellular processes. Its specific action on PPARγ, a nuclear receptor involved in adipogenesis, glucose homeostasis, and lipid metabolism, makes it a valuable tool for investigating the role of PPARγ in various physiological and pathological conditions.
| Catalog Number | I003111 |
| CAS Number | 313516-66-4 |
| Synonyms | 2-chloro-5-nitro-N-pyridin-4-ylbenzamide |
| Molecular Formula | C₁₂H₈ClN₃O₃ |
| Purity | ≥95% |
| Target | Vitamin D Related/Nuclear Receptor |
| Solubility | DMSO 26 mg/mL; Water <1.1 mg/mL |
| Storage | 3 years -20C powder |
| IC50 | 1 nM |
| InChI | InChI=1S/C12H8ClN3O3/c13-11-2-1-9(16(18)19)7-10(11)12(17)15-8-3-5-14-6-4-8/h1-7H,(H,14,15,17) |
| InChIKey | FRPJSHKMZHWJBE-UHFFFAOYSA-Nv |
| SMILES | C1=CC(=C(C=C1[N+](=O)[O-])C(=O)NC2=CC=NC=C2)Cl |
| Reference | </br>1:Corrigendum to /T0070907 inhibits repair of radiation-induced DNA damage by targeting RAD51/ [Toxicol. Vitro 37C (2016) 1-8]. An Z, Yu JR, Park WY.Toxicol In Vitro. 2017 Apr;40:347. doi: 10.1016/j.tiv.2016.11.013. Epub 2016 Dec 15. No abstract available. PMID: 27989574 </br>2:T0070907 inhibits repair of radiation-induced DNA damage by targeting RAD51. An Z, Yu JR, Park WY.Toxicol In Vitro. 2016 Dec;37:1-8. doi: 10.1016/j.tiv.2016.08.009. Epub 2016 Aug 18. PMID: 27544453 </br>3:T0070907, a PPAR γ inhibitor, induced G2/M arrest enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. An Z, Muthusami S, Yu JR, Park WY.Reprod Sci. 2014 Nov;21(11):1352-61. doi: 10.1177/1933719114525265. Epub 2014 Mar 18. PMID: 24642720 Free PMC Article</br>4:Peroxisome proliferator-activated receptor γ (PPARγ)-independent specific cytotoxicity against immature adipocytes induced by PPARγ antagonist T0070907. Kawahara A, Haraguchi N, Tsuchiya H, Ikeda Y, Hama S, Kogure K.Biol Pharm Bull. 2013;36(9):1428-34. PMID: 23995653 Free Article</br>5:The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms. Zaytseva YY, Wallis NK, Southard RC, Kilgore MW.Anticancer Res. 2011 Mar;31(3):813-23. PMID: 21498701 </br>6:The microtubule-targeting agent T0070907 induces proteasomal degradation of tubulin. Harris G, Schaefer KL.Biochem Biophys Res Commun. 2009 Oct 16;388(2):345-9. doi: 10.1016/j.bbrc.2009.08.009. Epub 2009 Aug 6. PMID: 19665001 </br>7:Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. Collin M, Murch O, Thiemermann C.Crit Care Med. 2006 Apr;34(4):1131-8. PMID: 16484917 </br>8:T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, Amaral K, Nakamura M, Miao S, Cao P, Learned RM, Chen JL, Li Y.J Biol Chem. 2002 May 31;277(22):19649-57. Epub 2002 Mar 4. PMID: 11877444 Free Article |
